Immunomonitoring of patients treated with CAR-T cells  for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

The objectives of this workshop were to determine, based on data from the literature and the experience of the centers, the immunological analyses to be carried out in patients treated with CAR-T cells. The recommendations relate to the characterization of the patient's immune cells at the time of apheresis, the characterization of the injected CAR-T cells, as well as the monitoring of the CAR-T cells and other parameters of immune reconstitution in the patient after administration of the treatment. Harmonization of practices will allow clinical-biological correlation studies to be carried out in patients treated in real life with the aim of identifying factors predictive of response and toxicity. Such data could have a major medico-economic impact by making it possible to identify the patients who will optimally benefit from these expensive treatments.PMID:34253335 | DOI:10.1016/j.bulcan.2021.04.008

Source: Bulletin du Cancer - July 13, 2021 Category: Cancer & Oncology Authors: Marie Th érèse Rubio Pauline Varlet Vincent Allain Caroline Ballot Alexis Cuffel Marina Deschamps Christophe Ferrand Jacques Foguenne Edouard Forcade Anne Huynh Am élie Guihot Jean-Baptiste Latouche Claude Lemarie Guillaume Martinroche Florence Morin S Source Type: research